Drugs that contain Sodium Thiosulfate
1. Pedmark patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596190 | FENNEC PHARMS INC | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
Jan, 2038
(13 years from now) | |
| US11617793 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
| US11510984 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
| US11291728 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2025 |
| Orphan Drug Exclusivity(ODE-384) | Sep 20, 2029 |
Market Authorisation Date: 20 September, 2022
Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administrat...
Dosage: SOLUTION;INTRAVENOUS
PEDMARK family patents
2. Sodium Thiosulfate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11753301 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Feb, 2030
(5 years from now) | |
| US9585912 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| US9345724 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| US8496973 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Mar, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10479686 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
| Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
Market Authorisation Date: 14 February, 2012
Treatment: Sodium thiosulfate injection is administered by intravenous injection; Sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning tha...
Dosage: SOLUTION;INTRAVENOUS
SODIUM THIOSULFATE family patents